Results 91 to 100 of about 35,844 (219)

The use of novel anticoagulants in non-valvular atrial fibrillation [PDF]

, 2013
Atrial Fibrillation (AF) occurs in 1-2% of the general population, making it the commonest sustained cardiac arrhythmia. It becomes more common as one gets older, with a prevalence of 5-15% at 80 years of age.
Cassar, Andrew
core  

Balancing the Benefits and Risks of 2 Doses of Dabigatran Compared With Warfarin in Atrial Fibrillation [PDF]

, 2013
ObjectivesThis study sought to compare the net clinical benefit of dabigatran 110 mg bid and 150 mg bid with that of warfarin in patients with atrial fibrillation (AF).BackgroundIn patients with AF, dabigatran 110 mg bid and 150 mg bid are associated ...
Connolly, Stuart J., Eikelboom, John W., Hart, Robert G., Oldgren, Jonas, Reilly, Paul, Wallentin, Lars, Yang, Sean, Yusuf, Salim   +7 more
core   +1 more source

Non‐Anticoagulant Heparin: An In Vitro Investigation of a Novel Therapeutic Approach for Oral Cancer

Oral Diseases, EarlyView.
ABSTRACT Background Oral squamous cell carcinoma (OSCC) represents a significant global oral health concern. Non‐anticoagulant heparin (NH) emerges as a promising solution considering the enhanced survival observed with anticoagulants in cancer treatment. Methods We used the MTS assay (0/24/48/72 h), scratch assay (MuviCyte, 0–18 h), invasion Matrigel (
S. A. Hamza, R. Paolini, N. M. O'Brien‐Simpson, W. Singleton, R. Patini, M. McCullough, A. Celentano   +6 more
wiley   +1 more source

Potentiation of thrombus instability: a contributory mechanism to the effectiveness of antithrombotic medications [PDF]

, 2018
© The Author(s) 2018The stability of an arterial thrombus, determined by its structure and ability to resist endogenous fibrinolysis, is a major determinant of the extent of infarction that results from coronary or cerebrovascular thrombosis.
A Gast, AD Michelson, B Labarthe, B Shen, C Patrono, CT Ammollo, D Capodanno, D Gailani, DA Gorog, Diana A. Gorog, DM Coenen, E Álvarez, ER Bates, F Kabirian, F Müller, F Semeraro, G Stephens, H Brogren, HE Speich, HE Speich, HJ Weiss, HJ Weiss, HR Baumgartner, J Zilberman-Rudenko, JD McFadyen, JI Weitz, JM Cosemans, JP Collet, JP Collet, K Hosokawa, K Nagatsuka, KS Sakariassen, L Valerio, LF Brass, M Cattaneo, M Farag, M Humbert, M Larsson, M Li, M Ungerer, MA Bailey, MI Furman, MJ Price, ML Montfoort von, MS Sabatine, P Andre, P Seizer, PA Borne von dem, PP Wadowski, R Hellmuth, R Nergiz-Unal, RA Ajjan, S Goto, S Goto, SA Shaya, SB Larsen, SJ Marciniak, T Heitzer, T Renné, VT Turitto, VT Turitto, WA Schumacher, WS Nesbitt, X Wang, Y Yano, YC Lau, ZM Ruggeri   +66 more
core   +1 more source

Efficacy and Safety of Direct Oral Anti‐Coagulants in Painful Venous Malformations in Children

Pediatric Dermatology, EarlyView.
ABSTRACT Direct oral anticoagulants (DOAC), including dabigatran, apixaban, and rivaroxaban, are increasingly used in adults for painful venous malformations (VMs) instead of subcutaneous drugs such as low molecular weight heparins or fondaparinux. However, these medications are poorly studied in children. In seven children with painful VMs and chronic
Olivia Boccara, Julie Bonigen, Véronique Soupre, Eve Puzenat, Annouk Bisdorff, Ludovic Drouet   +5 more
wiley   +1 more source

Comparison of Two High‐Power Ablation Strategies for Typical Atrial Flutter: Acute and Long‐Term Outcome

Annals of Noninvasive Electrocardiology, Volume 30, Issue 4, July 2025.
ABSTRACT Background Ablation of the cavo‐tricuspid isthmus (CTI) is the standard treatment for typical atrial flutter. High‐power strategies have been described to improve lesion efficacy and durability. Objective To compare the acute success, safety, and long‐term outcomes of two strategies of high‐power CTI ablation using 8‐mm gold‐tip nonirrigated ...
Wael Zaher, Lorenzo Marcon, Klaus‐Richard Ebinger, Antonio Sorgente   +3 more
wiley   +1 more source

Anticoagulation management for cardiopulmonary bypass using TEG® 6 s in a patient receiving both heparin and dabigatran

JA Clinical Reports
Background It is difficult to evaluate adequate dose of heparin for cardiopulmonary bypass (CPB) by activated clotting time (ACT) in a patient receiving both heparin and dabigatran because dabigatran can also prolong ACT.
Yu Kawada, Nobuyuki Katori, Keiko Kaji, Shoko Fujioka, Tomoki Yamaguchi   +4 more
doaj   +1 more source

The case for dosing dabigatran: how tailoring dose to patient renal function, weight and age could improve the benefit–risk ratio

Therapeutic Advances in Neurological Disorders, 2015
Dabigatran is increasingly being used in clinical practice for the thromboprophylaxis in atrial fibrillation as a convenient therapy that needs no drug level monitoring. However, analysis of the data of the same clinical trial that led to the adoption of
Apostolos Safouris, Nikos Triantafyllou, John Parissis, Georgios Tsivgoulis   +3 more
doaj   +1 more source

Concerns Regarding the Use of Dabigatran for Stroke Prevention in Atrial Fibrillation

Pharmaceuticals, 2012
Dabigatran is an oral thrombin inhibitor which has been approved in several countries as an alternative to vitamin-K-antagonists for the prevention of stroke or embolism in atrial fibrillation patients.
Josef Finsterer, Claudia Stöllberger
doaj   +1 more source

Atrial Fibrillation and Myocardial Infarction: A Systematic Review and Appraisal of Pathophysiologic Mechanisms [PDF]

, 2016
A growing body of evidence suggests that atrial fibrillation (AF) is associated with myocardial infarction (MI). However, incidence and management of MI in AF is still undefined. METHODS AND RESULTS: We searched MEDLINE via PubMed and Cochrane database
PASTORI, DANIELE, PIGNATELLI, Pasquale, Soliman, Elsayed Z, VIOLI, Francesco   +3 more
core   +1 more source